Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 6th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Revenue	EBITDA	Earnings	EPS	Rev. Y/Y	Rev. 5Y	Earn. Y/Y	Earn. 5Y	Earnings Date
GSK	GSK PLC	$98.13B	$42.89B	$10.28B	$7.33B	$3.61	5.51%	-0.34%	125.18%	-2.46%	2026-02-04
GRFS	GRIFOLS SA	$6.26B	$8.01B	$1.71B	$174.36M	$0.26	2.57%	5.57%	258.21%	-25.16%	2026-02-24
BMY	BRISTOL MYERS SQUIBB CO	$111.84B	$48.03B	$12.94B	$6.04B	$2.97	1.26%	4.05%	N/A	N/A	2026-02-05
LLY	ELI LILLY & CO	$1.03T	$59.42B	$24.40B	$18.41B	$20.49	45.41%	20.68%	120.56%	27.21%	2026-02-11
AMGN	AMGEN INC	$186.89B	$35.97B	$16.53B	$7.01B	$13.03	10.56%	7.56%	65.15%	0.85%	2026-02-02
MRK	MERCK & CO INC	$270.99B	$64.24B	$27.65B	$19.03B	$7.57	1.68%	11.98%	58.04%	10.72%	2026-02-03
GILD	GILEAD SCIENCES INC	$162.70B	$29.09B	$13.67B	$8.11B	$6.51	2.78%	4.67%	6,410.00%	46.04%	2026-02-10
AMRN	AMARIN CORP PLC	$343.29M	$226.73M	-$80.28M	-$86.19M	-$4.20	-5.93%	-17.41%	N/A	N/A
SNY	SANOFI	$117.47B	$50.74B	$18.05B	$10.74B	$4.34	18.08%	3.68%	139.57%	-2.50%	2026-01-29
AZN	ASTRAZENECA PLC	$284.24B	$58.13B	$19.64B	$9.40B	$3.04	13.52%	17.57%	44.87%	26.15%	2026-02-05
NVS	NOVARTIS AG	$279.27B	$56.37B	$28.18B	$14.39B	$7.37	12.88%	2.60%	-14.20%	18.68%	2026-02-04
JNJ	JOHNSON & JOHNSON	$526.41B	$92.15B	$39.78B	$25.12B	$10.43	5.08%	2.65%	72.97%	10.06%
ABBV	ABBVIE INC	$385.48B	$59.64B	$12.49B	$2.39B	$1.33	7.40%	7.97%	-53.82%	-22.48%	2026-01-29
OGN	ORGANON & CO	$2.53B	$6.30B	$1.56B	$501.00M	$1.93	-1.69%	N/A	-61.93%	N/A
BIIB	BIOGEN INC	$25.50B	$10.07B	$2.71B	$1.61B	$10.99	4.77%	-6.73%	-1.08%	-18.34%	2026-01-29
PFE	PFIZER INC	$148.40B	$62.79B	$15.84B	$9.83B	$1.72	3.89%	14.38%	126.32%	4.35%	2026-02-03
SCLX	SCILEX HOLDING CO	$87.46M	$40.36M	-$319.06M	-$375.84M	-$31.85	-26.82%	N/A	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$60.30M	$0.00	-$5.60M	-$48.71M	-$2.63	N/A	N/A	N/A	N/A
MDCX	MEDICUS PHARMA LTD	$29.52M	$0.00	-$29.72M	-$34.49M	-$2.15	N/A	N/A	N/A	N/A
NSRX	NASUS PHARMA LTD	$59.73M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2026-02-25

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jan 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: B, Financials: C, and AI: B.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -4 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 45.53% over the past year, overperforming other general drug manufacturer stocks by 12 percentage points.

2. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: C, and AI: C.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 38, which is -2 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 14 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 23.11% over the past year, underperforming other general drug manufacturer stocks by -10 percentage points.

Grifols Sa has an average 1 year price target of $10.00, an upside of 9.77% from Grifols Sa's current stock price of $9.11.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: C.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 12 points higher than the general drug manufacturer industry average of 40.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock lose -3.77% over the past year, underperforming other general drug manufacturer stocks by -37 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $56.67, an upside of 3.14% from Bristol Myers Squibb Co's current stock price of $54.94.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Bristol Myers Squibb Co, 33.33% have issued a Strong Buy rating, 11.11% have issued a Buy, 44.44% have issued a hold, while 0% have issued a Sell rating, and 11.11% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.76%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.76%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 51% indicates that its high dividend yield is sustainable for the long-term.

2. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 3.49%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.76%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its dividend yield is sustainable for the long-term.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) has an annual dividend yield of 3.44%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.76%. Gsk's dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 45.6% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.76% in the last day, and up 3.15% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 30 points higher than the general drug manufacturer industry average of 41. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -38.63% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -72 percentage points.

2. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 30 points higher than the general drug manufacturer industry average of 41. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 21.75% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -12 percentage points.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 57, which is 16 points higher than the general drug manufacturer industry average of 41. It passed 4 out of 7 valuation due diligence checks.

Grifols Sa's stock has gained 23.11% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -10 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 3.94% over the next year.

26.32% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 47.37% of general drug manufacturer stocks are rated B (Buy), 15.79% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 44.73x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.